GeoVax Sponsors 2025 Global Health Equity Summit to Advance Vaccine Access
GeoVax's sponsorship of the Dr. David Satcher Global Health Equity Summit highlights the biotechnology company's commitment to ensuring equitable global access to vaccines and therapies, particularly for immunocompromised and underserved populations.
GeoVax, Inc., a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced its sponsorship of the 3rd Annual Dr. David Satcher Global Health Equity Summit, hosted by Morehouse School of Medicine. The summit, taking place October 2, 2025, in Atlanta, Georgia, convenes global health experts, policymakers, researchers, community organizations, and students to address pressing challenges in health equity under the theme "The Quest for Health Equity & Justice: A Glocal Perspective."
This year's agenda focuses on how local innovations, policies, and partnerships can be scaled globally to close equity gaps in healthcare access. The 2025 Summit features keynote speaker Dr. John N. Nkengasong, U.S. Global AIDS Coordinator and Senior Bureau Official for Global Health Security and Diplomacy, alongside distinguished leaders from academic, government, and private sectors. Sessions will explore critical topics including vaccine access and trust, innovations in pandemic preparedness, and community-driven models for health equity.
Representing GeoVax at the Summit will be Mary Hauser, PhD, Director of Preclinical Research, who will be available throughout the event to discuss the Company's vaccine and immunotherapy programs. Dr. Hauser will highlight GeoVax's work advancing MVA-based vaccines designed specifically to meet the needs of immunocompromised and underserved populations, underscoring the Company's commitment to ensuring that scientific innovation translates into real-world accessibility for those most in need.
"Health equity is not just a goal - it is a mandate for global progress," said David Dodd, Chairman & CEO of GeoVax. "We are honored to support the Satcher Summit and partner with Morehouse School of Medicine in advancing solutions that ensure lifesaving vaccines and therapies reach those most in need." The sponsorship demonstrates GeoVax's strategic focus on addressing healthcare disparities through collaborative partnerships and innovative vaccine development.
GeoVax's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers, as a booster vaccine in patients with chronic lymphocytic leukemia, and as a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines. The company is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation. For more information about the current status of clinical trials and other updates, visit https://www.geovax.com.
The Dr. David Satcher Global Health Equity Summit, founded in honor of Dr. David Satcher, the 16th Surgeon General of the United States and Founding Director of the Satcher Health Leadership Institute, provides a platform for advancing health equity through research, innovation, and policy. Now in its third year, the event serves as a catalyst for collaboration and action to achieve sustainable change in global and community health, making GeoVax's participation particularly significant given the company's focus on developing vaccines for vulnerable populations.